Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.
As of today (2026-06-24), HLS Therapeutics's Volatility is 26.17%.
HLS Therapeutics (TSX:HLS) Volatility Explanation
Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.
Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.
Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
HLS Therapeutics Volatility Related Terms
TSX:HLS vs ZTS: Volatility Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics Volatility vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Volatility distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's Volatility falls into.
The annualized volatility is calculated as following:
σA
=
σM
*
√12
=
√ 1/(n-1) ∑(Ri - R')^2
*
√12
Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (TSX:HLS) has a Volatility of 26.17% as of Jun. 24, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on HLS Therapeutics and its competitors.
Is HLS Therapeutics' Volatility too high?
HLS Therapeutics' current Volatility is 26.17%. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Volatility compare to ZTS?
HLS Therapeutics' Volatility of 26.17% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Drug Manufacturers company?
A good Volatility depends on the Drug Manufacturers industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Volatility is 26.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.46, compared to a current price of C$4.42 — trading 0.9% below its estimated fair value. The current Volatility is 26.17%. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Volatility is 26.17% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.42 is trading 0.9% below its estimated GF Value™ of C$4.46.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
Volatility: 26.17%
GF Value™: C$4.46 vs. price of C$4.42 (0.9% below fair value)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score
Get the complete analysis for TSX:HLS
Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 